Clinical Trials Directory

If you decide to join this study, doctors will first check your medical history and the medicines you are taking to see if you can be part of it. If you qualify, you will have several tests, including: - A heart scan (CT or MRI) - An ultrasound of your heart - A full check-up, including your heart and brain if you had a stroke before - Blood tests to check things like salt levels, kidney and liver health, and heart function - A heart test called an ECG - A walking test to see how far you can walk in 6 minutes - A survey called the Kansas City Cardiomyopathy Questionnaire to learn how you feel Some visits may take a long time, up to 8 hours.

We are doing this study to find out if an experimental study drug called RP1 (the study drug) is a safe and effective option for people who have advanced melanoma. We want to know how the study drug works when it is combined with a cancer drug called nivolumab in comparison to several other standard treatments for advanced melanoma (nivolumab + relatlimab OR nivolumab alone OR pembrolizumab alone).

We are doing this study to find out if an experimental drug called RP2 (the study drug) is a safe and effective option for people who have uveal melanoma (melanoma in the eye). We want to know how well the study drug works when it is combined with a drug called nivolumab, and we will compare its outcomes to treatment with the drug combination of nivolumab + ipilimumab.

We are doing this study to find out if a drug called rosuvastatin (an FDA-approved medication for lowering cholesterol) can help reduce symptoms and extend the life expectancy of people with liver cirrhosis. Although rosuvastatin is an approved and commonly prescribed drug, it is not approved for the treatment of cirrhosis.

If you choose to join this study, you will first give your permission and take part in some starting tests. These include answering questions, doing fitness checks, and completing movement tasks. After that, you will be randomly placed into one of three groups: one group will do aerobic exercise, another will receive brain stimulation called rTMS, and the third group will do both. Each group will follow a 12-week treatment plan. After that, there will be follow-up check-ins at 12 weeks and again at 24 weeks. The entire study will last about 9 months.

We are doing this study to test a telehealth intervention that is designed to help women who are suffering from fatigue while taking parp inhibitors for their ovarian cancer. We want to know how well it works compared to current, standard clinical methods.

We are doing this study to see if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for treating colorectal or pancreatic cancer when it is combined with different chemotherapy drugs.